Long-term pirtobrutinib treatment for people with previously treated CLL/SLL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label long-term safety extension for participants who completed the parent LOXO-BTK-20020 (NCT04666038) study, providing continued access to pirtobrutinib or continued follow-up. Participants receive pirtobrutinib on a regular dosing schedule every 4 weeks and are monitored for adverse events and tolerability. The follow-up period for this extension is expected to last about five years, with periodic clinic visits and safety assessments. The trial is sponsored by Eli Lilly and conducted at several US oncology sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria:

* This is not applicable to this study

Where it's running

• Mitchell Cancer Institute
  Mobile, Alabama, United States Recruiting
• Cancer Specialists, LLC
  Jacksonville, Florida, United States Recruiting
• Minnesota Oncology Hematology, P.A.
  Coon Rapids, Minnesota, United States Recruiting
• Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
  New York, New York, United States Recruiting
• Oncology Hematology Care Inc
  Cincinnati, Ohio, United States Recruiting
• Texas Oncology - Paris
  Fort Worth, Texas, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• Comparing a BTK-targeted protein degrader (BGB-16673) with pirtobrutinib for adults with relapsed or refractory CLL or SLL

  This trial tests whether BGB-16673 works better and is as safe as pirtobrutinib for adults whose CLL or SLL has come back or not responded after prior covalent BTK inhibitor treatment.

  Recruiting at 217 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 216 other locations · NCT06973187

• Time-limited combination of pirtobrutinib, venetoclax and obinutuzumab for relapsed CLL/SLL

  This trial will test whether a time-limited combination of pirtobrutinib, venetoclax, and obinutuzumab can control relapsed CLL/SLL in adults who have had prior therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06967610

• Long-term pirtobrutinib continuation for people with previously treated CLL/SLL or non-Hodgkin lymphoma

  People who are already taking pirtobrutinib in an earlier trial can continue the drug or their follow-up visits so doctors can see if it stays safe and keeps helping over the long term.

  Recruiting at 25 sites Phase 4 Eli Lilly and Company · Miami, Florida and 35 other locations · NCT06876662

• Long-term safety follow-up of pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma

  This program lets people who previously received pirtobrutinib in a Lilly study continue treatment or follow-up so doctors can see if the drug remains safe over the long term.

  Recruiting at 32 sites Phase 4 Eli Lilly and Company · Jacksonville, Florida and 37 other locations · NCT06876649

• Treatment of Chronic Lymphocytic Leukaemia with Pirtobrutinib after Zanubrutinib

  This study is testing if the drug pirtobrutinib can help people with chronic lymphocytic leukaemia who didn’t respond to or relapsed after treatment with zanubrutinib.

  Recruiting Phase 2 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria and 2 other locations · NCT06812715

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.